prindace 4 milligram tablets
les laboratoires servier - perindopril tert-butylamine salt - tablets - 4 milligram - ace inhibitors, plain
prindace 2 milligram tablets
les laboratoires servier - perindopril tert-butylamine salt - tablets - 2 milligram - ace inhibitors, plain
prindace 8 milligram tablets
les laboratoires servier - perindopril tert-butylamine salt - tablets - 8 milligram - ace inhibitors, plain
princeton pharmacy sterile emergency eyewash
princeton pharmacy (s) private limited - ophthalmology - for chemical splash on eyes and skin, removal of foreign particles, mucous secretions and fluorescein dye used in diagnosis.
prilace ramipril 10mg capsule blister pack
arrotex pharmaceuticals pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; ethanol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; brilliant blue fcf; allura red ac; gelatin; phloxine b - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.
prilace ramipril 5 mg tablets blister pack
arrotex pharmaceuticals pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; calcium sulfate dihydrate; sodium bicarbonate; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.
prilace ramipril 2.5 mg tablets blister pack
arrotex pharmaceuticals pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; sodium bicarbonate; calcium sulfate dihydrate; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.
prilace ramipril 1.25 mg tablets blister pack
arrotex pharmaceuticals pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: calcium sulfate dihydrate; pregelatinised maize starch; sodium stearylfumarate; sodium bicarbonate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. postmyocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke or peripheral vascular disease. reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure above 160 mmhg or diastolic blood pressure above 90 mmhg (or on antihypertensive treatment); total cholesterol above 5.2mmol/l: hdl cholesterol less than 0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.
prilace
aspen pharma pty ltd - ramipril -
princess auto powerfoam c solution
princess auto ltd. - sodium hypochlorite - solution - 7.20% - sodium hypochlorite 7.20% - disinfectants (for agents used on object)